NCT06115603 · University of Arkansas, Fayetteville
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
(CBG)
What this study is about
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD.
View original scientific description
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Between 18 and 55-years-old.
- BMI between 18 and 35 kg/m2.
- Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
- Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
- Are not pregnant or currently breastfeeding.
- Have no history of significant allergic condition, hypersensitivity, or allergic reactions to cannabis, cannabinoid medications, hemp products, medium chain triglyceride oil, or peppermint.
- Have not used CBG or any other cannabinoid products in the past 30 days.
- Willing to abstain from using cannabis or any THC-containing product for the duration of the study.
- Have never used a synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), or a synthetic cannabinoid receptor agonist (e.g., spice, k2).
- Have not been exposed to any investigational drug or device 30 days prior to screening and you have no plans to take an investigational drug during the study.
- Willing to maintain a stable treatment regimen (i.e., no change in current medication use) for the duration of the study.
- Not currently taking a prescription medication for ADHD and have not been prescribed a medication for ADHD in the past six months.
- Not currently having thoughts of committing suicide
- Does not meet criteria for current severe major depressive disorder or a substance use disorder.
- Have not been diagnosed with bipolar disorder or psychosis.
- Do not have an acute illness, such as a respiratory infection or other illness that would interfere with study participation; not currently taking medication for an acute illness (e.g., antibiotic).
- Do not have history of diagnosis related to liver function and/or significantly impaired liver function (e.g., cirrhosis of the liver, hepatitis).
- Willing to ensure they have used effective contraception (for example, oral contraception, double barrier, intra-uterine device) for 30 prior to the study and for 30 days after study completion.
- Have access to a ride to the University of Arkansas campus for research appointments.
- Willing to comply with current university mandates as they pertain to COVID-19 protocols (e.g., mask wearing).
- Do not have any serious or unstable physical health conditions including neurological or renal illness.
- Do not have any current or historical cardiovascular conditions, including hypotension, bradycardia, or heart block.
- No atrial fibrillation, bradycardia, or tachycardia detected via mobile electrocardiogram during the in-laboratory visit.
- No recent illicit drug use other than cannabis, or alcohol use in the 12 hours preceding the in-laboratory visit.
- Not currently prescribed or taking the following medications:
- Valproic acid
- Phenobarbital
- Mechanistic Target of Rapamycin \[mTOR\] Inhibitors
- Oral tacrolimus
- St. John's wort
- Escitalopram
- Cardiovascular medications
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
Where
- Fayetteville, Arkansas
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced May 27, 2026 · Source of record for eligibility and locations